In patients with defective Excision Repair Cross-Complementation Group 1 (ERCC1), a particular homologous repair deficiency, with non-small cell lung cancer (NSCLC), PARPi therapy created cytoplasmic chromatin fragments that triggered cGAS/STING to produce type I IFNs and CCL5 [58]. The gene discussed is CCL5; the disease is non-small cell lung carcinoma.